Serum TNF-α levels as a biomarker in some liver diseases of Egyptian patients
Yameny, A., Alabd, S., Mansor, M. (2023). Serum TNF-α levels as a biomarker in some liver diseases of Egyptian patients. EKB Journal Management System, 5(1), 1-8. doi: 10.21608/jmals.2023.329303
Ahmed Abdelhalim Yameny; Sabah Farouk Alabd; Magda Ahmed M. Mansor. "Serum TNF-α levels as a biomarker in some liver diseases of Egyptian patients". EKB Journal Management System, 5, 1, 2023, 1-8. doi: 10.21608/jmals.2023.329303
Yameny, A., Alabd, S., Mansor, M. (2023). 'Serum TNF-α levels as a biomarker in some liver diseases of Egyptian patients', EKB Journal Management System, 5(1), pp. 1-8. doi: 10.21608/jmals.2023.329303
Yameny, A., Alabd, S., Mansor, M. Serum TNF-α levels as a biomarker in some liver diseases of Egyptian patients. EKB Journal Management System, 2023; 5(1): 1-8. doi: 10.21608/jmals.2023.329303

Serum TNF-α levels as a biomarker in some liver diseases of Egyptian patients

Journal of Medical and Life Science
Volume 5, Issue 1, March 2023, Page 1-8  XML PDF (1.34 MB)
Document Type: Original Article
DOI: 10.21608/jmals.2023.329303
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Abdelhalim Yameny email orcid 1; Sabah Farouk Alabd1; Magda Ahmed M. Mansor2
1Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt
2Department of Histology, Faculty of Medicine, Menoufia University, Egypt
Abstract
Background: Tumor necrosis factor alpha (TNF-α) is physiologically essential for a healthy immune response. Although TNF-α can help the immune system regulate, producing too much or inappropriate of it can be dangerous and can cause diseases. Patients and methods: this study was conducted on 90 patients with liver diseases and 25 healthy control G1, patients divided into 4 groups, (G2) 25 patients with HCV infection, (G3) 25 HCC+HCV infection, (G4) 25 patients with HBV infection, (G5) 15 patients with HCC + HBV. Results: There was a statistically significant difference between the five groups with p-value >0.001*, Compared to the control group the four groups HCV (G2), HCV+HCC (G3), HBV (G4), and HBV+HCC (G5) have the same statistically significant difference with the same (P1) p-value >0.001* which was significant. The serum TNF-α expression level of the HCV group (G2) was significantly elevated than HCV+HCC (G3) with a (P2) p-value of 0.010*significant. Still, the Serum TNF-α expression level of the HBV group (G4) was higher than HBV+HCC (G5) (61.05 ± 199.1, 14.36 ± 2.18 respectively) with (P7) p-value 0.960.
Conclusion: Serum TNF-α can used as a biomarker to differentiate between healthy and infected patients with HCV or HBV and the development of HCC.
Keywords
Tumor necrosis factor alpha (TNF-α); HBV; HCV; HCC; Liver diseases
Statistics
Article View: 68
PDF Download: 215